Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Carnitine in metabolic disease : potential for pharmacological intervention

Tools
- Tools
+ Tools

Arduini, Arduino, Bonomini, Mario, Savica, V., Amato, A and Zammit, Victor A. (2008) Carnitine in metabolic disease : potential for pharmacological intervention. Pharmacology & Therapeutics, Vol.120 (No.2). pp. 149-156. doi:10.1016/j.pharmthera.2008.08.008

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/j.pharmthera.2008.08.008

Request Changes to record.

Abstract

l-carnitine (LC) deficiency is commonly observed in chronic hemodialysis (HD) patients. As a result of this and other causes of secondary LC deficiencies, LC has been described as a “conditionally essential nutrient” or “conditional vitamin”. Although a large number of clinical trials regarding the beneficial effects of LC administration in HD patients have been published, some controversy about its use in this indication persists. In this article, we will review the use of LC in dialysis patients, by focussing mainly on those experimental and clinical data supporting the notion that supra-physiological concentrations of LC in plasma and target organs may exert beneficial effects on several metabolic parameters that have derangements of a common origin (e.g. insulin resistance, type 2 diabetes, dyslipidemia) and which are frequently present in end-stage renal disease (ESRD) patients undergoing dialysis.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Pharmacology & Therapeutics
Publisher: Elsevier Inc.
ISSN: 0163-7258
Official Date: November 2008
Dates:
DateEvent
November 2008Published
Volume: Vol.120
Number: No.2
Page Range: pp. 149-156
DOI: 10.1016/j.pharmthera.2008.08.008
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us